Fresenius continues steady growth:
This article was originally published in Clinica
First-quarter turnover at Fresenius rose 13% to DM 534 million ($368 million), almost entirely due to foreign business. Revenue breakdown by division was: dialysis technology 56%; pharmaceuticals 33%; critical care and diagnostics 7%; and project business 4%. Net income was DM 15 million, up 19% compared with 1994. Fresenius expects total sales in 1995 to rise 10%.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.